July 2026
1. LESNOCK JL, Temin S, Bouberhan S, Adams SF, et al
   Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0.
   J Clin Oncol. 2026 Jul 13:101200JCO2601591. doi: 10.1200/JCO-26-01591.
   

   >> Share

   
   June 2026
2. BERGAMINI A, Suyanto S, Savva C, Maher E, et al
   Malignant Adult Ovarian Germ Cell Tumors: An International Multicenter Study to Identify Relevant Prognostic Risk Factors for Stage IC and Beyond.
   J Clin Oncol. 2026;44:1720-1729.
   

   >> Share

   
   February 2026
3. APOSTOL AI, Gronwald J, Cybulski C, Kim RH, et al
   Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2.
   J Clin Oncol. 2026 Feb 28:JCO2501648. doi: 10.1200/JCO-25-01648.
   

   >> Share

   
   January 2026
4. SLOMOVITZ BM, Weroha SJ, Deng W, Chon HS, et al
   Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026).
   J Clin Oncol. 2026;44:153-163.
   

   >> Share

   
   December 2025
5. HARTER P, Marme F, Redondo A, Reuss A, et al
   Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial.
   J Clin Oncol. 2025 Dec 3:JCO2501210. doi: 10.1200/JCO-25-01210.
   

   >> Share

   
   October 2025
6. SHAH M, Fiero MH, Cheng J, Chen TY, et al
   Reply to: Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer.
   J Clin Oncol. 2025 Oct 31:JCO2501933. doi: 10.1200/JCO-25-01933.
   

   >> Share

   
   
7. MONK BJ, Coleman RL, O'Malley DM, Moore KN, et al
   Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer.
   J Clin Oncol. 2025 Oct 31:JCO2501721. doi: 10.1200/JCO-25-01721.
   

   >> Share

   
   
8. BANERJEE SN, Van Nieuwenhuysen E, Aghajanian C, D'Hondt V, et al
   Erratum: Efficacy and Safety of Avutometinib +/- Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.
   J Clin Oncol. 2025 Oct 13:JCO2502377. doi: 10.1200/JCO-25-02377.
   

   >> Share

   
   July 2025
9. KONSTANTINOPOULOS PA, Kim JW, Freyer G, Lee JY, et al
   Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation.
   J Clin Oncol. 2025 Jul 23:JCO2500225. doi: 10.1200/JCO-25-00225.
   

   >> Share

   
   
10. SEWASTJANOW-SILVA M, Xiao L, Abdelhakeem A, Pabon CM, et al
    Survival Benefit of Palliative Oophorectomy for Patients With Ovarian Metastasis From Baseline Metastatic Gastric Adenocarcinoma.
    J Clin Oncol. 2025;43:2361-2371.
    

    >> Share

    
    
11. BANERJEE SN, Van Nieuwenhuysen E, Aghajanian C, D'Hondt V, et al
    Efficacy and Safety of Avutometinib +/- Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.
    J Clin Oncol. 2025 Jul 11:JCO2500112. doi: 10.1200/JCO-25-00112.
    

    >> Share

    
    May 2025
12. SHAH M, Chen TY, Ison G, Fiero MH, et al
    Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.
    J Clin Oncol. 2025 May 19:JCO2402834. doi: 10.1200/JCO-24-02834.
    

    >> Share

    
    January 2025
13. GAILLARD S, Lacchetti C, Armstrong DK, Cliby WA, et al
    Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update.
    J Clin Oncol. 2025 Jan 22:JCO2402589. doi: 10.1200/JCO-24-02589.
    

    >> Share

    
    December 2024
14. SCAMBIA G, Villalobos Valencia R, Colombo N, Cibula D, et al
    Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results.
    J Clin Oncol. 2024 Dec 12:JCO2400933. doi: 10.1200/JCO.24.00933.
    

    >> Share

    
    November 2024
15. FAGOTTI A, Costantini B, Fanfani F, Giannarelli D, et al
    Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Randomized Trial on Survival Evaluation (HORSE; MITO-18).
    J Clin Oncol. 2024 Nov 21:JCO2400686. doi: 10.1200/JCO.24.00686.
    

    >> Share

    
    October 2024
16. CHLEBOWSKI RT, Aragaki AK, Pan K, Haque R, et al
    Menopausal Hormone Therapy and Ovarian and Endometrial Cancers: Long-Term Follow-Up of the Women's Health Initiative Randomized Trials.
    J Clin Oncol. 2024;42:3537-3549.
    

    >> Share

    
    
17. BERGSTROM EN, Abbasi A, Diaz-Gay M, Galland L, et al
    Deep Learning Artificial Intelligence Predicts Homologous Recombination Deficiency and Platinum Response From Histologic Slides.
    J Clin Oncol. 2024;42:3550-3560.
    

    >> Share

    
    
18. LEE JM, Brady MF, Miller A, Moore RG, et al
    Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.
    J Clin Oncol. 2024 Oct 3:JCO2400683. doi: 10.1200/JCO.24.00683.
    

    >> Share

    
    September 2024
19. GONZALEZ-MARTIN A, Rubio MJ, Heitz F, Depont Christensen R, et al
    Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.
    J Clin Oncol. 2024 Sep 18:JCO2400668. doi: 10.1200/JCO.24.00668.
    

    >> Share

    
    August 2024
20. O'BRIEN KM, Wentzensen N, Ogunsina K, Weinberg CR, et al
    Intimate Care Products and Incidence of Hormone-Related Cancers: A Quantitative Bias Analysis.
    J Clin Oncol. 2024;42:2645-2659.
    

    >> Share

    
    May 2024
21. LANDEN CN, Buckanovich RJ, Sill MW, Mannel RS, et al
    Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.
    J Clin Oncol. 2024 May 22:JCO2302076. doi: 10.1200/JCO.23.02076.
    

    >> Share

    
    
22. HARRIS HR, Davis CP, Terry KL
    Epidemiologic Methods to Advance Our Understanding of Ovarian Cancer Risk.
    J Clin Oncol. 2024 May 15:JCO2400602. doi: 10.1200/JCO.24.00602.
    

    >> Share

    
    April 2024
23. MUTLU SUTCUOGLU B, Sutcuoglu O
    Interpretation of the EORTC-55954 Trial: Does the Response to Neoadjuvant Chemotherapy Have an Effect on Disease Outcome?
    J Clin Oncol. 2024;42:1204-1205.
    

    >> Share

    
    
24. HAN CY, Lu KH, Corrigan G, Perez A, et al
    Normal Risk Ovarian Screening Study: 21-Year Update.
    J Clin Oncol. 2024;42:1102-1109.
    

    >> Share

    
    February 2024
25. LORUSSO D, Raspagliesi F, Ronzulli D, Valabrega G, et al
    Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.
    J Clin Oncol. 2024 Feb 5:JCO2301225. doi: 10.1200/JCO.23.01225.
    

    >> Share

    
    
26. PAVLIK EJ, van Nagell JR Jr, Dietrich CS 3rd, Ueland FR, et al
    Compelling Story of Ovarian Cancer Screening.
    J Clin Oncol. 2024 Feb 2:JCO2302424. doi: 10.1200/JCO.23.02424.
    

    >> Share

    
    January 2024
27. TJOKROWIDJAJA A, Friedlander ML, Ledermann JA, Coleman RL, et al
    Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor.
    J Clin Oncol. 2024 Jan 12:JCO2301182. doi: 10.1200/JCO.23.01182.
    

    >> Share

    
    November 2023
28. LAVERY JA, Boutros PC, Scott JM, Tammela T, et al
    Pan-Cancer Analysis of Postdiagnosis Exercise and Mortality.
    J Clin Oncol. 2023;41:4982-4992.
    

    >> Share

    
    
29. ST LAURENT J, Liu JF
    Treatment Approaches for Platinum-Resistant Ovarian Cancer.
    J Clin Oncol. 2023 Nov 1:JCO2301771. doi: 10.1200/JCO.23.01771.
    

    >> Share

    
    October 2023
30. AREND RC, Monk BJ, Shapira-Frommer R, Haggerty AF, et al
    Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).
    J Clin Oncol. 2023 Oct 31:JCO2202915. doi: 10.1200/JCO.22.02915.
    

    >> Share

    
    September 2023
31. OZOLS RF, Bundy BN, Greer BE, Fowler JM, et al
    Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study.
    J Clin Oncol. 2023;41:4077-4083.
    

    >> Share

    
    
32. SPRIGGS DR, Fleming GF
    Flashback Foreword: Cytoreductive Surgery for Ovarian Carcinoma and Carboplatin + Paclitaxel in Ovarian Cancer.
    J Clin Oncol. 2023;41:4063-4064.
    

    >> Share

    
    August 2023
33. KURTZ JE, Pujade-Lauraine E, Oaknin A, Belin L, et al
    Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial.
    J Clin Oncol. 2023 Aug 29:JCO2300529. doi: 10.1200/JCO.23.00529.
    

    >> Share

    
    
34. MCCAW ZR, Tian L, Wei LJ
    Evaluating the Duration of Response With Mirvetuximab Soravtansine for Treating Platinum-Resistant Ovarian Cancer.
    J Clin Oncol. 2023 Aug 3:JCO2300288. doi: 10.1200/JCO.23.00288.
    

    >> Share

    
    June 2023
35. COLOMBO N, Van Gorp T, Matulonis UA, Oaknin A, et al
    Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study.
    J Clin Oncol. 2023 Jun 26:JCO2202624. doi: 10.1200/JCO.22.02624.
    

    >> Share

    
    May 2023
36. KINNEY AY, Walters ST, Lin Y, Lu SE, et al
    Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk Communication and Navigation Intervention: Large Effect Size but Room to Grow.
    J Clin Oncol. 2023;41:2767-2778.
    

    >> Share

    
    
37. STROOT IAS, Brouwer J, Bart J, Hollema H, et al
    High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of BRCA1/2 Pathogenic Variants: Prevalence and Clinical Factors.
    J Clin Oncol. 2023;41:2523-2535.
    

    >> Share

    
    March 2023
38. FU S, Yao S, Yuan Y, Previs RA, et al
    Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification.
    J Clin Oncol. 2023;41:1725-1734.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share